Heart Disease & Cardiology Clinical Trials Update: Week 23, 2026

Published June 5, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

This Phase 3 trial is exploring a new drug called REGN7508, which is a monoclonal antibody, to prevent stroke and systemic embolism in adults with atrial fibrillation. It compares REGN7508 to apixaban, a commonly used blood thinner. The study aims to find a safer and effective option for stroke prevention and plans to enroll over 15,000 participants at multiple locations in the future.

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

This Phase 4 trial focuses on women with coronary artery disease who do not have obstructive blockages in their arteries. It tests an intensive medication approach including statins, ACE inhibitors or ARBs, and aspirin to reduce risks of heart attacks, strokes, and hospitalizations. The study has completed recruitment across more than 80 sites in the United States and Puerto Rico, potentially offering a new treatment strategy tailored for women.

Inclisiran Effectiveness in China: a Pragmatic Randomized Trial

This Phase 4 trial evaluates inclisiran, an injection that lowers cholesterol, in Chinese patients with coronary heart disease. Inclisiran may provide longer-lasting cholesterol control with fewer doses compared to current treatments. Results are expected after one year of treatment, and if successful, this could become an important option to manage cholesterol and reduce heart disease risk.

Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions

This Phase 4 study is testing whether giving flu shots before hospital discharge can help patients recovering from serious heart conditions like heart attacks or heart failure. The goal is to reduce infections and further heart problems after leaving the hospital. The trial is currently recruiting in Poland and will follow patients for six months to see if vaccination improves outcomes.

Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes

This ongoing study compares two medications, tirzepatide and semaglutide, in adults who are overweight or obese and have cardiovascular risk but do not have diabetes. The trial aims to determine which medication more effectively lowers the risk of heart attacks and strokes while managing weight. It is enrolling many participants in the United States and may provide new options for heart health and weight management.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.